JP2008526836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526836A5 JP2008526836A5 JP2007550301A JP2007550301A JP2008526836A5 JP 2008526836 A5 JP2008526836 A5 JP 2008526836A5 JP 2007550301 A JP2007550301 A JP 2007550301A JP 2007550301 A JP2007550301 A JP 2007550301A JP 2008526836 A5 JP2008526836 A5 JP 2008526836A5
- Authority
- JP
- Japan
- Prior art keywords
- sibutramine
- bromate
- hydrogen sulfate
- acid salt
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004425 sibutramine Drugs 0.000 claims 25
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 23
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 9
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims 7
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 claims 6
- -1 inorganic acid salt Chemical class 0.000 claims 6
- 238000002441 X-ray diffraction Methods 0.000 claims 5
- TWHXWYVOWJCXSI-UHFFFAOYSA-N phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O TWHXWYVOWJCXSI-UHFFFAOYSA-N 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 239000013078 crystal Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20050001405 | 2005-01-06 | ||
| PCT/KR2006/000073 WO2006073292A1 (en) | 2005-01-06 | 2006-01-06 | Inorganic acid salts of sibutramine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526836A JP2008526836A (ja) | 2008-07-24 |
| JP2008526836A5 true JP2008526836A5 (https=) | 2008-11-27 |
Family
ID=36647751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007550301A Pending JP2008526836A (ja) | 2005-01-06 | 2006-01-06 | シブトラミンの無機酸塩 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7432398B2 (https=) |
| EP (1) | EP1846359A4 (https=) |
| JP (1) | JP2008526836A (https=) |
| KR (1) | KR100830002B1 (https=) |
| CN (1) | CN101098850B (https=) |
| WO (1) | WO2006073292A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060080818A (ko) * | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 술폰산염 |
| KR20060080817A (ko) * | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 디카복실산염 |
| KR100814384B1 (ko) * | 2006-02-10 | 2008-03-18 | 대화제약 주식회사 | 시부트라민 염을 함유하는 약학 조성물 및 이의 제조방법 |
| KR100800561B1 (ko) * | 2006-03-29 | 2008-02-04 | 주식회사 삼오제약 | 시부트라민 술포닐염의 제조방법 및 이를 포함하는비만관련 질환 예방 및 치료용 약학조성물 |
| EP2044043B2 (en) | 2006-06-16 | 2021-03-03 | H. Lundbeck A/S | 1- ý[- (2, 4-dimethylphenylsulfanyl) -phenyl]piperazine hydrobromide as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment |
| CN102786444A (zh) * | 2012-07-24 | 2012-11-21 | 上海瑞博化学有限公司 | 一种西布曲明类似物的磺酸盐的制备方法 |
| CN105566327A (zh) * | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
| HUE062000T2 (hu) * | 2018-10-31 | 2023-09-28 | Servier Lab | BCL-2 inhibitor új sója, vonatkozó kristályforma, ezek elõállítási eljárása és ezeket tartalmazó gyógyszerkészítmények |
| MX2023014302A (es) * | 2021-06-04 | 2024-02-28 | Repare Therapeutics Inc | Formas cristalinas, composiciones que contienen las mismas y métodos para su uso. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52768B1 (en) | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| GB2184122B (en) | 1985-12-17 | 1989-10-18 | Boots Co Plc | N,n-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methyl butylamine hydrochloride monohydrate |
| GB8704777D0 (en) | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
| JP2675573B2 (ja) | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
| IE61928B1 (en) | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| US5459164A (en) | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
| GB9402641D0 (en) * | 1994-02-11 | 1994-04-06 | Boots Co Plc | Therapeutic agents |
| GB9619961D0 (en) * | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
| US6331571B1 (en) * | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6046242A (en) * | 1998-11-27 | 2000-04-04 | Basf Aktiengesellschaft | Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence |
| AU3757800A (en) * | 1999-03-19 | 2000-10-09 | Abbott Gmbh & Co. Kg | Method of controlling weight gain associated with therapeutic drugs |
| WO2000056310A1 (en) * | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of chronic fatigue syndrome |
| JP2001050883A (ja) * | 1999-08-05 | 2001-02-23 | Akashi Corp | 複合機能材料試験機 |
| BR0105486A (pt) | 2001-09-27 | 2003-10-07 | Libbs Farmaceutica Ltda | Novo composto farmacêutico, seus processos de obtenção e composições farmacêuticas contendo o mesmo |
| JP4278652B2 (ja) | 2002-10-05 | 2009-06-17 | ハンミ ファーム． シーオー．， エルティーディー． | 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物 |
| KR100536750B1 (ko) * | 2002-10-05 | 2005-12-16 | 한미약품 주식회사 | 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는약학 조성물 |
| GB0310361D0 (en) * | 2003-05-06 | 2003-06-11 | Cipla Ltd | Pharmaceutical compound |
| KR20060080818A (ko) | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 술폰산염 |
| KR20060080817A (ko) | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 디카복실산염 |
-
2006
- 2006-01-06 WO PCT/KR2006/000073 patent/WO2006073292A1/en not_active Ceased
- 2006-01-06 CN CN2006800018259A patent/CN101098850B/zh not_active Expired - Fee Related
- 2006-01-06 KR KR1020060001929A patent/KR100830002B1/ko not_active Expired - Fee Related
- 2006-01-06 JP JP2007550301A patent/JP2008526836A/ja active Pending
- 2006-01-06 US US10/580,136 patent/US7432398B2/en not_active Expired - Fee Related
- 2006-01-06 EP EP06700096A patent/EP1846359A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526836A5 (https=) | ||
| JP2020511461A5 (https=) | ||
| JP2010180243A5 (https=) | ||
| JP2014515008A5 (https=) | ||
| FR2912742B1 (fr) | Procede de synthese d'acrylonitrile a partir de glycerol | |
| JP2010536889A5 (https=) | ||
| JP2014521726A5 (https=) | ||
| WO2009056791A1 (en) | Processes for preparing pharmaceutical compounds | |
| JP2007512362A5 (https=) | ||
| EP3137083A2 (en) | Novel polymorphic forms of vortioxetine and its pharmaceutically acceptable salts | |
| US9212166B2 (en) | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof | |
| JP2014510746A5 (https=) | ||
| BRPI0507329A (pt) | polimorfos cristalinos de um ligante do receptor de cxc-quimiocina | |
| JO2926B1 (en) | Organic compounds | |
| JP2011529942A5 (https=) | ||
| DK1820792T3 (da) | Fremgangsmåde til fremstilling af adamantanaminer | |
| JP2009062360A (ja) | シナカルセットの製造方法 | |
| KR20100135970A (ko) | 알리스키렌 유리 염기의 고체 상태 | |
| EP2649044A1 (en) | Method for synthesising substituted aminocyclohexanone derivatives | |
| WO2008008327A3 (en) | Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound | |
| JP2008526835A5 (https=) | ||
| NO20070845L (no) | Fremgangsmate for fremstilling av losartan | |
| JP2008526836A (ja) | シブトラミンの無機酸塩 | |
| WO2008015005A3 (en) | Polymorphic forms of ziprasidone sulfates | |
| RU2010134904A (ru) | Кристаллическая форма абакавира, которая, по существу, свободна от растворителя |